Upfront Fee & Equity Premium was Fate Therapeutics’s largest product and service line in fiscal 2018, bringing in $2.10M of $4.30M (49%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|
| Upfront Fee & Equity Premium | $2.10M | $2.10M | $2.10M |
| Research Services | $2.30M | $2.00M | $2.00M |
| Upfront Fee | — | — | $200.00K |
| Total | $4.40M | $4.10M | $4.30M |
Fate Therapeutics brought in $4.30M from its three product and service lines in fiscal 2018, the year ended December 31, 2018. Fate Therapeutics regrouped these lines after fiscal 2017, so the total does not compare directly with that year's $4.10M. Upfront Fee & Equity Premium was the largest at $2.10M (48.8%), ahead of Research Services at $2.00M (46.5%) and Upfront Fee at $200.00K (4.7%).
Compared with fiscal 2017, Upfront Fee & Equity Premium grew 0.0% to $2.10M and Research Services grew 0.0% to $2.00M.
Fate Therapeutics began breaking out Upfront Fee in fiscal 2018, when it brought in $200.00K.
Fate Therapeutics (FATE) reports its revenue by product and service. In fiscal 2018, Upfront Fee & Equity Premium was its largest product and service line, bringing in $2.10M (48.8% of the total), followed by Research Services at $2.00M (46.5%).
Upfront Fee & Equity Premium was Fate Therapeutics' largest product and service line in fiscal 2018, bringing in $2.10M, or 48.8% of the $4.30M total across its three product and service lines.
Every figure comes from Fate Therapeutics' annual financial filings, as reported. Each line keeps the name Fate Therapeutics gives it, and years follow its fiscal calendar.
Fate Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.